ArticleTranslational cancer research2026
AMOT mediates YAP1 activation and promotes the cell progression and glycolysis in non-small cell lung cancer by modulating the Hippo signaling pathway.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) exhibits aggressive cell progression and profound metabolic reprogramming. This study investigated the clinical significance, functional role, and molecular mechanism of the Angiomotin (AMOT)/Yes-associated protein 1 (YAP1)/Hippo axis in regulating NSCLC growth and glycolysis. Methods: AMOT expression was analyzed in 68 paired NSCLC and adjacent normal tissues. Results: AMOT was significantly upregulated in NSCLC tissues, correlating with larger tumor size (≥4 cm), advanced clinical stage, and poorer overall survival. Conclusions: The AMOT/YAP1/Hippo axis acts as a crucial driver of NSCLC progression and aerobic glycolysis, offering a promising therapeutic target for NSCLC intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.